Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep73 | Adrenal and Cardiovascular Endocrinology | ECE2022

A rare cause of Cushing’s syndrome

Favero Vittoria , Aresta Carmen , Parazzoli Chiara , Morelli Valentina , Chiodini Iacopo

Introduction: Aggressive ACTH-independent Cushing’s syndrome is rare and frequently related to malignant adrenocortical tumor. However, in exceptional situations, ectopic steroids secretion has been described.Case report: We report the case of an 87 years-old woman referred to our clinic in September 2020 after a low trauma sacral fracture. Her recent medical history revealed the onset, in the previous months, of severe hypokalemia, uncontrolled typ...

ea0081ep116 | Adrenal and Cardiovascular Endocrinology | ECE2022

Metyrapone treatment in bilateral macronodular adrenal hyperplasia: a report of two cases

Favero Vittoria , Aresta Carmen , Parazzoli Chiara , Chiodini Iacopo , Morelli Valentina

Introduction Primary bilateral macronodular adrenal hyperplasia (PBMAH) is potentially responsible for variable degree of cortisol excess. In patients with PBMAH the complete remission of cortisol hypersecretion can be achieved only by performing bilateral adrenalectomy, leading to a persistent hypocortisolism and to a consequent need of a lifelong glucocorticoid replacement therapy. Therefore, bilateral adrenalectomy is worth doing only in patients with severe hypercortisolis...

ea0090ep848 | Pituitary and Neuroendocrinology | ECE2023

Opposite tumoral and hormonal responses to low-dose pasireotide in Cushing’s Disease

Serban Andreea , Zampetti Benedetta , Saladino Andrea , Chiodini Iacopo , Cozzi Renato

Pasireotide (Pas) is a multireceptor-targeted somatostatin analogue approved for the treatment of patients with Cushing’s Disease (CD) who fail or are poor candidates to surgery. Pas markedly improves signs and symptoms of the disease, reduces urinary free cortisol (UFC) up to its normalization in 55% of patients and pituitary tumour size in up to 100%. Here we present a patient with severe recurrent CD treated with Pas and showing opposite results between hormonal levels...

ea0070aep17 | Adrenal and Cardiovascular Endocrinology | ECE2020

A double-blind, randomized, placebo-controlled phase 3 study to assess the efficacy and safety of relacorilant, a selective glucocorticoid receptor modulator, in patients with hypercortisolism due to cortisol-secreting adrenal adenoma(s)/hyperplasia

Chiodini Iacopo , Grauer Andreas , Moraitis Andreas , Terzolo Massimo

Relacorilant is a highly selective glucocorticoid receptor modulator that antagonizes the effects of excess cortisol while showing no significant affinity for the mineralocorticoid and progesterone receptors. In a Phase 2 study in patients with endogenous hypercortisolism, relacorilant demonstrated improvements in glycemic and hypertension control with no treatment-related hypokalemia or antiprogesterone effects. An international, multicenter, Phase 3 clinical trial, using ran...

ea0070aep589 | Pituitary and Neuroendocrinology | ECE2020

The cushing’s collaborative patient survey results

Valassi Elena , Tabarin Antoine , Chiodini Iacopo , Feelders Richard , Andela Cornelie

Background: Early diagnosis of Cushing’s syndrome and initiation of effective treatment are essential to limit long-term morbidity and early mortality. However, diagnosis is often delayed due to the non-specificity of symptoms, or because symptoms are not recognised by physicians, leading to more complex treatment needs and a worsening of patient quality of life. A survey was conducted to better understand the patient experience of Cushing’s syndrome and the true b...

ea0081p6 | Adrenal and Cardiovascular Endocrinology | ECE2022

Primary aldosteronism and microprolactinoma: a new syndromic variant?

Parazzoli Chiara , Favero Vittoria , Morelli Valentina , Aresta Carmen , Chiodini Iacopo , Falchetti Alberto

Introduction: Primary aldosteronism (PA) has been described in association with endocrine and non-endocrine neoplasms. Aldosterone-producing adenomas mainly associate with hyperparathyroidism, prolactinomas and pancreatic endocrine tumors, particularly in the context of multiple endocrine neoplasia type 1 MEN1 syndrome. Next-generation sequencing (NGS) studies have shown frequent somatic mutations underlying PA and, rarely, germline mutations of CYP11B1/CYP11B2</e...

ea0081p277 | Adrenal and Cardiovascular Endocrinology | ECE2022

Presenting clinical features of Cushing’s syndrome and non-classic hypercortisolism

Delle Donne Elisa , Parazzoli Chiara , Favero Vittoria , Chiodini Iacopo , Morelli Valentina , Aresta Carmen

Background: The Endocrine Society Guidelines recommend screening for hypercortisolism especially in patients with specific features that best discriminate Cushing’s Syndrome (CS): easy bruising, facial plethora, proximal myopathy and striae. Clinical experience suggests that these features, though suggestive of hypercortisolism, are not enough sensitive. Indeed, patients with hypercortisolism frequently manifest primarily less discriminatory cortisol-related features, suc...

ea0081p191 | Reproductive and Developmental Endocrinology | ECE2022

FSH and bone: comparison between males with central vs primary hypogonadism

Giovanelli Luca , Cangiano Biagio , Colombo Stefano , Persani Luca , Quinton Richard , Bonomi Marco , Chiodini Iacopo

Background: Recent data suggest a direct effect of follicle stimulating hormone (FSH) on the skeletal metabolism. Particularly, it can encourage bone resorption and also inhibit osteoblast differentiation. High FSH levels have been found to correlate with impaired bone health in females, whilst evidence in males remains somewhat poor and conflicting. Intriguingly, men with primary and central hypogonadism might represent a novel study model in this context.<p class="abstex...

ea0037ep53 | Adrenal cortex | ECE2015

Beneficial effects of replacement therapy with modified-release hydrocortisone in patients with adrenal insufficiency

Morelli Valentina , Messina Erika , Mendola Marco , Cairoli Elisa , Ambrosi Bruno , Cannavo Salvatore , Chiodini Iacopo , Spada Anna

Introduction: The classical replacement therapy for hypoadrenalism may expose patients to non-physiologic glucocorticoids levels with negative metabolic consequences. Up to now, one study demonstrated that, as compared to the classical treatment, a modified-release hydrocortisone (MRH), improves weight, blood pressure, glycaemic control and QoL in a 3-month follow-up period. Few data are available on the long-term persistence of these benefits.Design/met...

ea0070aep134 | Bone and Calcium | ECE2020

Radiofrequency Echographic Multi Spectrometry (REMS) evaluation in patients with primary osteoporosis and primary hyperparathyroidism

Grassi Giorgia , Palmieri Serena , Cairoli Elisa , Chiodini Iacopo , Arosio Maura , Eller Vainicher Cristina

Background: Radiofrequency Echographic Multi Spectrometry (REMS) is a new ultrasound-based tool for bone mineral density (BMD) measurement, recently approved by FDA for the use in clinical routine to diagnose osteoporosis (OP) and to monitor bone changes. However, data on patients with secondary OP are not available. The aim of our study was to compare REMS and DXA ability in identifying clinical (cFX) and morphometric vertebral fractures (VFx) in patients with primary OP (pOP...